Quercetin Nano-formulations as a Potential Approach for Skin Cancer.

Q2 Pharmacology, Toxicology and Pharmaceutics

Pharmaceutical nanotechnology Pub Date : 2024-12-10 DOI:10.2174/0122117385332427241112034005

Harshad Kapare, Sunil Kanadje, Ritesh Bhole

{"title":"Quercetin Nano-formulations as a Potential Approach for Skin Cancer.","authors":"Harshad Kapare, Sunil Kanadje, Ritesh Bhole","doi":"10.2174/0122117385332427241112034005","DOIUrl":null,"url":null,"abstract":"<p><p>Quercetin, a natural flavonoid, is well-proven for anticancer properties in a variety of cancers. Quercetin's anticancer action is driven by its anti-inflammatory and antioxidant properties. It inhibits pro-inflammatory cytokines (e.g., TNF-α, IL-6) and suppresses NF-κB and COX-2, reducing tumor growth. Its antioxidant activity neutralizes reactive oxygen species (ROS), preventing oxidative damage that can lead to cancer. However, quercetin faces challenges such as poor solubility, bioavailability, instability, low skin penetration, rapid metabolism, and potential systemic toxicity at high doses, which limit its therapeutic application. Nanocarrier systems such as liposomes, polymeric nanoparticles (PLGA-based), solid lipid nanoparticles (SLNs), and nanoemulsions have been developed to address these issues. These formulations enhance quercetin's penetration, stability, and bioavailability, improving its effectiveness against skin cancers by promoting controlled release and targeted delivery. Nanocarriers offer a promising solution to overcome these limitations and enhance its anticancer potential.</p>","PeriodicalId":19774,"journal":{"name":"Pharmaceutical nanotechnology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical nanotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0122117385332427241112034005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Quercetin, a natural flavonoid, is well-proven for anticancer properties in a variety of cancers. Quercetin's anticancer action is driven by its anti-inflammatory and antioxidant properties. It inhibits pro-inflammatory cytokines (e.g., TNF-α, IL-6) and suppresses NF-κB and COX-2, reducing tumor growth. Its antioxidant activity neutralizes reactive oxygen species (ROS), preventing oxidative damage that can lead to cancer. However, quercetin faces challenges such as poor solubility, bioavailability, instability, low skin penetration, rapid metabolism, and potential systemic toxicity at high doses, which limit its therapeutic application. Nanocarrier systems such as liposomes, polymeric nanoparticles (PLGA-based), solid lipid nanoparticles (SLNs), and nanoemulsions have been developed to address these issues. These formulations enhance quercetin's penetration, stability, and bioavailability, improving its effectiveness against skin cancers by promoting controlled release and targeted delivery. Nanocarriers offer a promising solution to overcome these limitations and enhance its anticancer potential.

查看原文本刊更多论文

槲皮素纳米制剂作为治疗皮肤癌的潜在方法。

槲皮素是一种天然的类黄酮，已被证明对多种癌症具有抗癌作用。槲皮素的抗癌作用是由它的抗炎和抗氧化特性驱动的。抑制促炎因子（如TNF-α、IL-6），抑制NF-κB、COX-2，抑制肿瘤生长。它的抗氧化活性中和活性氧（ROS），防止可能导致癌症的氧化损伤。然而，槲皮素面临溶解度差、生物利用度低、不稳定、皮肤渗透性低、代谢快以及高剂量时潜在的全身毒性等挑战，这限制了其治疗应用。纳米载体系统如脂质体、聚合物纳米颗粒（基于plga）、固体脂质纳米颗粒（sln）和纳米乳液已经被开发出来以解决这些问题。这些配方增强槲皮素的渗透、稳定性和生物利用度，通过促进控制释放和靶向递送来提高其抗皮肤癌的有效性。纳米载体为克服这些限制和增强其抗癌潜力提供了一个有希望的解决方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceutical nanotechnology Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

4.20

自引率

0.00%

发文量

期刊介绍： Pharmaceutical Nanotechnology publishes original manuscripts, full-length/mini reviews, thematic issues, rapid technical notes and commentaries that provide insights into the synthesis, characterisation and pharmaceutical (or diagnostic) application of materials at the nanoscale. The nanoscale is defined as a size range of below 1 µm. Scientific findings related to micro and macro systems with functionality residing within features defined at the nanoscale are also within the scope of the journal. Manuscripts detailing the synthesis, exhaustive characterisation, biological evaluation, clinical testing and/ or toxicological assessment of nanomaterials are of particular interest to the journal’s readership. Articles should be self contained, centred around a well founded hypothesis and should aim to showcase the pharmaceutical/ diagnostic implications of the nanotechnology approach. Manuscripts should aim, wherever possible, to demonstrate the in vivo impact of any nanotechnological intervention. As reducing a material to the nanoscale is capable of fundamentally altering the material’s properties, the journal’s readership is particularly interested in new characterisation techniques and the advanced properties that originate from this size reduction. Both bottom up and top down approaches to the realisation of nanomaterials lie within the scope of the journal.